International Flavors & Fragrances
IFF
$84.28
+1.07%
International Flavors & Fragrances Inc. (IFF) is the world's largest specialty ingredients producer, supplying flavors, fragrances, health and biosciences solutions, and food ingredients to industries including food, beverage, personal care, and pharmaceuticals. The company differentiates itself through its proprietary formulations and global leadership in probiotics and enzymes, with a diversified portfolio spanning four key segments. Currently, the investor narrative centers on IFF's strategic divestiture of its Food Ingredients business, expected to close in 2027, which is seen as a catalyst to streamline operations and reduce debt. Additionally, recent market commentary highlights IFF as an undervalued S&P 500 stock poised for a rebound, supported by improving profitability and a strong analyst consensus.…
IFF
International Flavors & Fragrances
$84.28
Related headlines
IFF 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on International Flavors & Fragrances's 12-month outlook, with a consensus price target around $95.66 and implied upside of +13.5% versus the current price.
Average Target
$95.66
0 analysts
Implied Upside
+13.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$76 - $105
Analyst target range
The target price range spans from $76.00 (low) to $105.00 (high), representing a wide spread of 38% from low to high, which reflects moderate uncertainty about the pace of margin recovery and the impact of the Food Ingredients divestiture. The high target of $105 implies a forward PE of approximately 26.5x, suggesting the market is pricing in successful execution of the divestiture and robust growth in the remaining segments. The low target of $76 suggests a scenario where margin expansion stalls or the divestiture faces delays. Recent institutional ratings show no downgrades, with firms like Morgan Stanley, Citigroup, and JP Morgan maintaining Overweight or Buy ratings, indicating a stable and positive sentiment.
Drowning in data?
Find the real signal!
IFF Technical Analysis
IFF's stock is in a clear recovery uptrend, with a 1-year price change of +27.4% and a YTD gain of +23.9%. The current price of $84.28 sits at 84.2% of its 52-week range (low $59.14, high $89.32), indicating the stock is trading near the upper end of its range, reflecting strong momentum and investor confidence. This positioning suggests the market is rewarding the company's operational improvements and strategic initiatives, though it also raises the risk of short-term overextension.
Beta
0.94
0.94x market volatility
Max Drawdown
-23.1%
Largest decline past year
52-Week Range
$59-$89
Price range past year
Annual Return
+27.4%
Cumulative gain past year
| Period | IFF Return | S&P 500 |
|---|---|---|
| 1m | +9.2% | +3.6% |
| 3m | +12.0% | +2.7% |
| 6m | +3.6% | +11.4% |
| 1y | +27.4% | +18.7% |
| ytd | +23.9% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IFF Fundamental Analysis
IFF's revenue trajectory shows a mixed picture: Q1 2026 revenue was $2.741 billion, down 3.6% YoY, but this follows a pattern of sequential stabilization after a challenging 2025. The company's revenue segments show a balanced portfolio, with Taste ($656M) and Scent ($651M) each contributing roughly 24% of total revenue, while Health & Biosciences ($595M) and Food Ingredients ($839M) make up the remainder. The slight revenue decline is partly due to the planned divestiture of Food Ingredients, which is expected to streamline the portfolio and potentially improve growth quality.
Quarterly Revenue
$2.7B
2026-03
Revenue YoY Growth
-3.6%
YoY Comparison
Gross Margin
37.1%
Latest Quarter
Free Cash Flow
$398000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IFF Overvalued?
IFF's valuation is best assessed using the forward PE ratio, as the trailing PE is negative (-46.2x) due to non-recurring charges and impairments in the past year. The forward PE of 21.3x is more meaningful, reflecting the market's expectation of normalized earnings. The gap between the negative trailing PE and positive forward PE indicates that the market is looking past historical losses and pricing in a significant earnings recovery, supported by the PEG ratio of 0.18, which suggests the stock is undervalued relative to its expected growth.
PE
-46.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 8x~340x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.9x
Enterprise Value Multiple
